115 related articles for article (PubMed ID: 11318801)
21. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Pro-C global for identification of defects in protein C/S anticoagulant pathway.
Bin Hanif T; Anwar J; Idrees M
J Ayub Med Coll Abbottabad; 2011; 23(1):89-91. PubMed ID: 22830156
[TBL] [Abstract][Full Text] [Related]
23. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
Matsumoto T; Nogami K; Shima M
Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530
[TBL] [Abstract][Full Text] [Related]
24. Laboratory tests for protein C deficiency.
Khor B; Van Cott EM
Am J Hematol; 2010 Jun; 85(6):440-2. PubMed ID: 20309856
[TBL] [Abstract][Full Text] [Related]
25. Activated protein C resistance and lupus anticoagulant in pregnancy.
Busowski JD; Jenkins AD; Hale EU; Busowski M; Dacus JV
J Matern Fetal Med; 1999; 8(6):298-9. PubMed ID: 10582865
[TBL] [Abstract][Full Text] [Related]
26. The Activated Seven Lupus Anticoagulant (ASLA) test has comparable sensitivity to classical assays for screening of lupus anticoagulant.
Marinuzzo M; Adamczuk Y; Varela ML; Pombo G; Forastiero R
Thromb Haemost; 2005 May; 93(5):1007-9. PubMed ID: 15900652
[No Abstract] [Full Text] [Related]
27. An improved test to identify aPC-resistant factor V-Leiden.
Preda L; Erba N; Figini S; Carniti GC; Rossi E
Thromb Res; 1997 Jun; 86(6):461-8. PubMed ID: 9219326
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism.
Toulon P; Adda R; Perez P
Thromb Res; 2001 Oct; 104(2):93-103. PubMed ID: 11672753
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of four coagulation tests to detect plasma lupus anticoagulants.
Saxena R; Saraya AK; Kotte VK; Singh YN; Prasad L; Malviya AN
Am J Clin Pathol; 1991 Dec; 96(6):755-8. PubMed ID: 1746492
[TBL] [Abstract][Full Text] [Related]
30. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies.
Proven A; Bartlett RP; Moder KG; Chang-Miller A; Cardel LK; Heit JA; Homburger HA; Petterson TM; Christianson TJ; Nichols WL
Mayo Clin Proc; 2004 Apr; 79(4):467-75. PubMed ID: 15065611
[TBL] [Abstract][Full Text] [Related]
31. Endotoxaemia induces resistance to activated protein C in healthy humans.
de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vlasuk GP; Rote WE; Levi M; Büller HR; Meijers JC
Br J Haematol; 2006 Jul; 134(2):213-9. PubMed ID: 16846480
[TBL] [Abstract][Full Text] [Related]
32. Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism.
Ichiyama M; Ohga S; Ochiai M; Tanaka K; Matsunaga Y; Kusuda T; Inoue H; Ishimura M; Takimoto T; Koga Y; Hotta T; Kang D; Hara T
Pediatr Res; 2016 Jan; 79(1-1):81-6. PubMed ID: 26372516
[TBL] [Abstract][Full Text] [Related]
33. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
Favaloro EJ; Kershaw G; Mohammed S; Lippi G
Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
[TBL] [Abstract][Full Text] [Related]
34. Significant influence of the instrument on the result of the ProC Global assay. A multicenter evaluation using lyophilized plasmas and frozen plasma samples from carriers and non-carriers of the factor V Leiden mutation.
Toulon P; Lequerrec A; Piquet P; Robert A; Biron C
Thromb Res; 2002 Aug; 107(3-4):181-8. PubMed ID: 12431487
[No Abstract] [Full Text] [Related]
35. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.
Martorell JR; Muñoz-Castillo A; Gil JL
Thromb Haemost; 1995 Aug; 74(2):796-7. PubMed ID: 8585026
[No Abstract] [Full Text] [Related]
36. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
De Bel AV; Van der Cruyssen GA; Devreese KM
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
[TBL] [Abstract][Full Text] [Related]
37. Activated partial thromboplastin time derivative curves: helpful diagnostic tool in mixing test interpretation.
Esmedere Eren S; Karakukcu C; Ciraci MZ; Ustundag Y; Karakukcu M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):410-414. PubMed ID: 29708898
[TBL] [Abstract][Full Text] [Related]
38. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
Kraus M; Zander N; Fickenscher K
Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a new venom-based clotting assay of protein C.
Cooper PC; Cooper SM; Goodfellow KJ; Hickey KP; Kitchen S; Makris M
Int J Lab Hematol; 2008 Oct; 30(5):437-43. PubMed ID: 19046320
[TBL] [Abstract][Full Text] [Related]
40. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation.
Jennings I; Kitchen S; Woods TA; Preston FE; Greaves M
Thromb Haemost; 1997 May; 77(5):934-7. PubMed ID: 9184405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
